The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).

3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a designer drug of the pyrrolidinophenone-type, was first seized in Germany in 2009. It was also identified in 'legal high' samples investigated in the UK. Therefore, the aim of the presented work was to identify its in vivo and in vitro phase I and II metabolites using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-ion trap mass spectrometry (LC-MS(n) ). Furthermore, detectability of MDPBP in rat and human urine using standard urine screening approaches (SUSA) by GC-MS and LC-MS(n) was studied. The metabolites were isolated either directly or after enzymatic cleavage of conjugates by solid-phase extraction (C18, HCX). The metabolites were then analyzed and structures proposed after GC-MS (phase I) and LC-MS(n) (phase II). Based on these identified metabolites, the following main metabolic steps could be proposed: demethylenation followed by methylation of one hydroxy group, aromatic and side chain hydroxylation, oxidation of the pyrrolidine ring to the corresponding lactam as well as ring opening to the corresponding carboxylic acid. Furthermore, in rat urine after a typical user's dose as well as in human urine, mainly the metabolites could be detected using the authors' SUSA by GC-MS and LC-MS(n) . Thus, it should be possible to monitor an application of MDPBP assuming similar toxicokinetics in humans. Finally, CYP2C19 and CYP2D6 could be identified as the isoenzymes mainly responsible for demethylenation.

[1]  A. Servin,et al.  Effects of pyrovalerone on peripheral noradrenergic mechanisms. , 1978, Biochemical pharmacology.

[2]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[3]  H. Maurer,et al.  Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. , 2009, Journal of mass spectrometry : JMS.

[4]  U. Girreser,et al.  Spectroscopic characterization of 3,4-methylenedioxypyrrolidinobutyrophenone: a new designer drug with α-pyrrolidinophenone structure. , 2011, Forensic science international.

[5]  E. Fornal.  Identification of substituted cathinones: 3,4-Methylenedioxy derivatives by high performance liquid chromatography-quadrupole time of flight mass spectrometry. , 2013, Journal of pharmaceutical and biomedical analysis.

[6]  Folker Westphal,et al.  Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. , 2009, Forensic science international.

[7]  H. Sumnall,et al.  Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. , 2011, Drug testing and analysis.

[8]  M. Meyer,et al.  Metabolism of designer drugs of abuse: an updated review. , 2010, Current drug metabolism.

[9]  J. Deschamps,et al.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. , 2006, Journal of medicinal chemistry.

[10]  G. Mulder,et al.  The dependence of the rate of sulphate conjugation on the plasma concentration of inorganic sulphate in the rat in vivo. , 1982, Biochemical pharmacology.

[11]  C L Crespi,et al.  The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future. , 1999, Pharmacology & therapeutics.

[12]  S. Clarke.  In vitro assessment of human cytochrome P450. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  M. Meyer,et al.  Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept , 2011, Analytical and bioanalytical chemistry.

[14]  J. O'Brien,et al.  The analysis of amphetamine-like cathinone derivatives using positive electrospray ionization with in-source collision-induced dissociation. , 2012, Rapid communications in mass spectrometry : RCM.

[15]  Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry , 2008, Analytical and bioanalytical chemistry.

[16]  H. Maurer,et al.  Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  D. Zuba,et al.  Prevalence and co-existence of active components of 'legal highs'. , 2013, Drug testing and analysis.

[18]  F. Peters,et al.  New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  B. Miljković,et al.  Mass spectrometric investigation of 2-aminopropiophenones and some of their metabolites. , 1991, Rapid Communications in Mass Spectrometry.

[20]  M. Meyer,et al.  Development of the first metabolite-based LC-MSn urine drug screening procedure-exemplified for antidepressants , 2011, Analytical and bioanalytical chemistry.

[21]  H. Maurer,et al.  Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  P. O'Byrne,et al.  Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system. , 2013, Journal of analytical toxicology.

[23]  C. Vollmar,et al.  New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. , 2012, Journal of mass spectrometry : JMS.

[24]  Frank T Peters,et al.  Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. , 2010, Clinical chemistry.

[25]  H. Maurer,et al.  Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  F. Peters,et al.  Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography–mass spectrometry , 2002 .

[27]  M. Meyer,et al.  Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn) , 2011, Analytical and Bioanalytical Chemistry.

[28]  M. Meyer,et al.  Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. , 2010, Journal of mass spectrometry : JMS.

[29]  M. Meyer,et al.  Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents , 2011, Analytical and Bioanalytical Chemistry.

[30]  S. Polsky,et al.  The biotransformation of nitrogen containing xenobiotics to lactams. , 2000, Current drug metabolism.

[31]  M. Meyer,et al.  Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. , 2009, Chemical research in toxicology.

[32]  M. Meyer,et al.  New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. , 2009, Journal of mass spectrometry : JMS.

[33]  G. Gardos,et al.  A controlled evaluation of pyrovalerone in chronically fatigued volunteers. , 1973, International pharmacopsychiatry.

[34]  H. Shin,et al.  Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. , 1996, Journal of analytical toxicology.